{"id":31565,"date":"2022-11-11T10:33:14","date_gmt":"2022-11-11T10:33:14","guid":{"rendered":"https:\/\/zeepedia.com\/?p=31565"},"modified":"2022-11-12T10:12:01","modified_gmt":"2022-11-12T10:12:01","slug":"wilate","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/wilate\/","title":{"rendered":"Wilate &#8211; Human\u00a0von Willebrand factor and coagulation factor VIII uses, dose and side effects"},"content":{"rendered":"\n<p>Wilate, 500 IU VWF\/500 IU FVIII, powder and liquid for solution for injection,&nbsp;Wilate, 1000 IU VWF\/1000 IU FVIII, powder and liquid for solution for&nbsp;injection.<br>Human&nbsp;von Willebrand factor\/human&nbsp;coagulation factor&nbsp;VIII.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Wilate is and what it is used for<\/h2>\n\n\n\n<p>Wilate belongs to the pharmacotherapeutic group of drugs called coagulation factors and contains&nbsp;human&nbsp;von Willebrand factor (VWF) and&nbsp;coagulation factor&nbsp;VIII.&nbsp;Both of these&nbsp;proteins&nbsp;are important for the blood&#8217;s ability to clot (&nbsp;coagulation ability&nbsp;).<\/p>\n\n\n\n<p>von Willebrand disease<\/p>\n\n\n\n<p>Wilate is used to treat and prevent bleeding in patients with&nbsp;von Willebrand disease&nbsp;(VWS), which is a group of related diseases.&nbsp;VWS (&nbsp;von Willebrand disease&nbsp;) is a disorder of blood coagulation, which means that bleeding can last longer than expected.&nbsp;It is either due to a lack of VWF or to VWF not working properly.<\/p>\n\n\n\n<p>Hemophilia&nbsp;A<\/p>\n\n\n\n<p>Wilate is used to treat and prevent bleeding in patients with&nbsp;hemophilia&nbsp;A. This is a disease that means that you bleed for longer than normal.&nbsp;It is due to a congenital deficiency of&nbsp;factor VIII&nbsp;in the blood.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before using Wilate<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Wilate<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>If you are allergic to&nbsp;human&nbsp;von Willebrand factor,&nbsp;coagulation factor&nbsp;VIII, or any of the other ingredients of this medicine (listed in section 6).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and precautions<\/h2>\n\n\n\n<p>Talk to your doctor or pharmacist before using Wilate.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>All medicines of the same type as Wilate which are made from human blood (containing\u00a0proteins\u00a0) and are injected into a\u00a0vessel\u00a0(\u00a0intravenous\u00a0administration\u00a0) can cause allergic reactions.\u00a0Be aware of early signs of allergic reactions (\u00a0hypersensitivity reaction\u00a0), such as\u00a0hives- skin rash- pressure over the chest- wheezing- low\u00a0blood pressure\u00a0(may appear as dizziness)-\u00a0anaphylaxis\u00a0(when any or all of the above symptoms appear quickly and are intense)<\/li><\/ul>\n\n\n\n<p>If such symptoms occur, discontinue use immediately and contact your physician.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>When medicines are made from\u00a0human\u00a0plasma\u00a0or blood, special measures are taken to prevent\u00a0infection\u00a0from being passed on to patients.\u00a0This includes careful selection of blood and plasma donors to ensure that people at risk of infection are excluded, testing of individual donations and plasma pools for signs of virus\/infection, and also steps in the processing of blood or\u00a0plasma\u00a0that may inactivate or shed\u00a0viruses.\u00a0Despite this, the risk of transmission of\u00a0infection\u00a0cannot be completely excluded when medicines made from human blood or\u00a0plasma\u00a0are given.\u00a0This also applies to new, so far unknown\u00a0viruses as well as other types of\u00a0infection. The measures taken are considered to be effective against enveloped\u00a0viruses, such as\u00a0HIV,\u00a0hepatitis\u00a0B, and\u00a0hepatitis\u00a0C\u00a0viruses,\u00a0and for non-enveloped\u00a0viruses\u00a0and\u00a0hepatitis\u00a0A\u00a0virus.\u00a0The measures may be of limited value against non-enveloped\u00a0viruses\u00a0such as parvovirus B19. Parvovirus B19\u00a0infection can be serious for pregnant women (\u00a0infection\u00a0of the fetus), individuals with compromised immune systems, or patients with certain types of\u00a0anemia\u00a0(eg, sickle cell disease or\u00a0hemolytic anemia\u00a0).<br><br>When you are given Wilate, it is recommended that the product name and batch number be recorded to enable tracking of the product used.<\/li><\/ul>\n\n\n\n<p>Your doctor may suggest vaccination against&nbsp;hepatitis&nbsp;A and B if you are regularly\/repeatedly treated with plasma-derived VWF\/factor VIII concentrates.<\/p>\n\n\n\n<p>von Willebrand disease&nbsp;(VWS)<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>See section 4 (&nbsp;von Willebrand&#8217;s disease&nbsp;(VWS)) for&nbsp;side effects&nbsp;of VWS treatment.<\/li><\/ul>\n\n\n\n<p>Hemophilia&nbsp;A<\/p>\n\n\n\n<p>The development of inhibitors (\u00a0antibodies\u00a0) is a known complication that can occur with treatment with all\u00a0factor VIII\u00a0drugs.\u00a0The inhibitors prevent, especially at high levels, the treatment from working as it should.\u00a0You or your child will be closely monitored for the development of such inhibitors.\u00a0Tell your doctor immediately if you or your child develop bleeding that cannot be controlled with Wilate.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>See section 4 (\u00a0Haemophilia\u00a0A) for\u00a0side effects\u00a0in the treatment of\u00a0hemophilia\u00a0A.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Wilate<\/h2>\n\n\n\n<p>Tell your doctor or pharmacist if you are using, have recently used, or might be using other medicines.<\/p>\n\n\n\n<p>Although there is no known effect of other medicines on Wilate, tell your doctor or pharmacist if you are taking or have recently taken any other medicines (including medicines obtained without a prescription).<\/p>\n\n\n\n<p>Wilate must not be mixed with any other medicine during\u00a0the injection.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy, breastfeeding, and fertility<\/h2>\n\n\n\n<p>If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Wilate contains sodium<\/h2>\n\n\n\n<p>This medicine contains up to 58.7 mg of&nbsp;sodium&nbsp;(the main ingredient in common\/table salt) per bottle of 500 IU VWF and FVIII and up to 117.3 mg per bottle of 1000 IU VWF and FVIII.&nbsp;This corresponds to 2.94% and 5.87% respectively of the maximum recommended daily intake of&nbsp;sodium&nbsp;for adults.<br><a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to use Wilate<\/h2>\n\n\n\n<p>Wilate should be injected into a blood vessel (&nbsp;intravenous&nbsp;administration&nbsp;) after being dissolved in the supplied diluent.&nbsp;Treatment must be started under the supervision of a doctor.<\/p>\n\n\n\n<p><strong>Dosage<\/strong><\/p>\n\n\n\n<p>Your doctor will decide what&nbsp;dose&nbsp;you should have and how often you should take Wilate.&nbsp;Always use Wilate as directed by your doctor.&nbsp;Ask your doctor or pharmacist if you are unsure.<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you have taken too much Wilate<\/h2>\n\n\n\n<p>No symptoms of overdose with\u00a0human\u00a0VWF or factor VIII have been reported.\u00a0However, you should not take more than the prescribed\u00a0dose.<\/p>\n\n\n\n<p>If you have ingested too much medicine or if, for example,\u00a0a child has swallowed the medicine by mistake, contact a doctor or hospital for an assessment of the risk and advice.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you forget to take Wilate<\/h2>\n\n\n\n<p>Do not take a double to compensate for a missed\u00a0dose.<\/p>\n\n\n\n<p>If you have any further questions about this medicine, ask your doctor or pharmacist.<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause\u00a0side effects, although not everybody gets them.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Hypersensitivity or allergic reactions have been observed, although this is\u00a0<strong>rare<\/strong>.\u00a0Such reactions may include:- burning and stinging sensation at the infusion site- shiver- skin redness- headache-\u00a0hives\u00a0(\u00a0urticaria\u00a0)- low\u00a0blood pressure\u00a0(\u00a0hypotension\u00a0)- fatigue (\u00a0lethargy\u00a0)- nausea- restlessness- palpitations (\u00a0tachycardia\u00a0)- pressure over the chest- tingling sensation (ant crawls)- vomiting- wheezing- sudden swelling in different parts of the body (\u00a0angioedema\u00a0)<\/li><\/ul>\n\n\n\n<p>If you experience any of the above symptoms, inform your doctor.<\/p>\n\n\n\n<p>You should stop taking Wilate and contact your doctor immediately if you develop symptoms of\u00a0angioedema, such as:<\/p>\n\n\n\n<p>&#8211; Swelling of the tongue, face, or throat (pharynx)<\/p>\n\n\n\n<p>&#8211; Difficult to swallow<\/p>\n\n\n\n<p>&#8211;&nbsp;Hives&nbsp;and difficulty breathing<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Although\u00a0<strong>less common<\/strong>, fever has also been observed.<\/li><li>Abdominal pain, back pain, chest pain, cough, and dizziness may also occur, but the frequencies of these\u00a0side effects\u00a0are not known.<\/li><li>In\u00a0very rare\u00a0cases, hypersensitivity can lead to a severe\u00a0allergic reaction\u00a0called\u00a0anaphylaxis\u00a0(when any or all of the above symptoms appear quickly and are intense), which includes\u00a0shock.\u00a0If anaphylactic\u00a0shock\u00a0occurs, it is of the utmost importance that treatment is given according to current medical recommendations.<\/li><\/ul>\n\n\n\n<p>von Willebrand disease&nbsp;(VWS)<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>When a VWF product containing\u00a0factor VIII\u00a0is used to treat VWS, the treatment may lead to an excessive increase in\u00a0factor VIII\u00a0in the blood.\u00a0This can increase the risk of blood flow disturbances (blood clots).<br>If you are a patient with risk factors identified by a doctor or through laboratory tests, you must be checked for early signs of blood clots.\u00a0Preventive treatment (\u00a0prophylaxis\u00a0) against blood clots must be prescribed by your doctor by current recommendations.<\/li><li>Patients with\u00a0von Willebrand disease\u00a0(especially type 3 patients) may develop inhibitors (neutralizing\u00a0antibodies\u00a0) against VWF during treatment with VWF.\u00a0In these very rare cases, the inhibitors may cause Wilate not to work correctly.<br>If the bleeding does not stop, your blood should be tested for the presence of such inhibitors.<br>Inhibitors may increase the risk of suffering severe allergic reactions (anaphylactic\u00a0shock\u00a0).\u00a0If you suffer an\u00a0allergic reaction, you should be tested for the presence of inhibitors.<br>If inhibitors are detected in the blood, contact a doctor experienced in treating patients with bleeding disorders.\u00a0For patients with high levels of inhibitors, other types of treatment may be effective and should be considered.<\/li><\/ul>\n\n\n\n<p>Hemophilia&nbsp;A<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Among children who have not been treated with\u00a0factor VIII\u00a0medicines before, it is very common for inhibitory\u00a0antibodies\u00a0to develop (see section 2) (occurs in more than 1 in 10 patients).\u00a0However, for patients who have previously been treated with\u00a0factor VIII\u00a0(treatment more than 150 days), the risk is lower and the complication is less common (occurring in fewer than 1 in 100 users).\u00a0If you or your child develop\u00a0antibodies, the medicines may stop working as they should, and you or your child may suffer from persistent bleeding.\u00a0If this happens, contact a doctor immediately.<\/li><\/ul>\n\n\n\n<p>Inhibitors may increase the risk of suffering severe allergic reactions (anaphylactic\u00a0shock\u00a0).\u00a0If you suffer an\u00a0allergic reaction, you should be tested for the presence of inhibitors.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><em>Uncommon:<\/em>\u00a0may occur in up to 1 in 100 patients are:\u00a0\u00a0may occur in up to 1 in 1,000 patients very<em> rare:<\/em>\u00a0may occur in up to 1 in 10,000 patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>There are insufficient data to recommend the use of Wilate in previously untreated patients.<\/p>\n\n\n\n<p>There is limited experience in the treatment of children under six years of age.<\/p>\n\n\n\n<p>For infectious agent safety information, see section 2 (Warnings and precautions).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to store Wilate<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n<p>Store the powder and liquid in a refrigerator (2\u00b0C-8\u00b0C).<\/p>\n\n\n\n<p>Do not freeze.<\/p>\n\n\n\n<p>Store the vials in the outer carton.&nbsp;Light sensitive.<\/p>\n\n\n\n<p>Use before the expiry date stated on the label.<\/p>\n\n\n\n<p>Wilate can be stored at room temperature (max. +25\u00b0C) for 2 months.&nbsp;In such a case, the shelf life expires 2 months after the product was first taken out of the refrigerator.&nbsp;You must write down the new expiry date on the outer carton yourself.<\/p>\n\n\n\n<p>The powder should not be dissolved until immediately before\u00a0injection.\u00a0The solution is stable for 4 hours at room temperature.\u00a0However, to prevent contamination of the solution, it should be used immediately and only once.<\/p>\n\n\n\n<p>Medicines must not be thrown into the drain or among the household waste.\u00a0Ask the pharmacist how to dispose of medicines that are no longer used.\u00a0These measures will help to protect the environment.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Contents declaration:<\/h2>\n\n\n\n<p>&#8211; The active substances are\u00a0the human\u00a0von Willebrand factor and\u00a0human\u00a0coagulation factor\u00a0VIII.<\/p>\n\n\n\n<p>&#8211; Other ingredients are sodium chloride,\u00a0glycine, sucrose, sodium citrate, and calcium chloride.\u00a0Diluent: water for injections with 0.1% polysorbate 80.<\/p>\n\n\n\n<p><strong>Appearance and package sizes of the medicine<\/strong><\/p>\n\n\n\n<p>Freeze-dried powder: white or pale yellow powder or crumbly mass.<\/p>\n\n\n\n<p>Reconstituted solution: should be clear or slightly milky.<\/p>\n\n\n\n<p>Wilate is supplied as powder and liquid for solution for&nbsp;injection&nbsp;in two pack sizes:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Wilate 500 IU VWF and 500 IU FVIII, powder and liquid for solution for\u00a0injection, has a nominal content of 500 IU\u00a0human\u00a0von Willebrand factor and 500 IU\u00a0human\u00a0coagulation factor\u00a0VIII per\u00a0vial.\u00a0The product contains approximately 100 IU\/ml\u00a0human\u00a0von Willebrand factor and 100 IU\/ml\u00a0human\u00a0coagulation factor\u00a0VIII after dissolution in 5 ml water for injections with 0.1% polysorbate 80 (\u00a0diluent\u00a0).<\/li><li>Wilate 1000 IU VWF and 1000 IU FVIII, powder and liquid for solution for\u00a0injection, has a nominal content of 1000 IU\u00a0human\u00a0von Willebrand factor and 1000 IU\u00a0human\u00a0coagulation factor\u00a0VIII per\u00a0vial.\u00a0The product contains approximately 100 IU\/ml\u00a0human\u00a0von Willebrand factor and 100 IU\/ml\u00a0human\u00a0coagulation factor\u00a0VIII after dissolution in 10 ml water for injections with 0.1% polysorbate 80 (\u00a0diluent\u00a0).<\/li><\/ul>\n\n\n\n<p><strong>Package contents<\/strong><\/p>\n\n\n\n<p>1&nbsp;vial&nbsp;of freeze-dried powder<\/p>\n\n\n\n<p>1&nbsp;vial&nbsp;with&nbsp;diluent<\/p>\n\n\n\n<p>1 pack of&nbsp;intravenous&nbsp;injection&nbsp;equipment (1 transfer set, 1 infusion set, 1 disposable syringe)<\/p>\n\n\n\n<p>2 disinfection dryers<\/p>\n\n\n\n<p><strong>Marketing Authorization Holder and Manufacturer:<\/strong><\/p>\n\n\n\n<p><strong>Marketing Authorisation Holder:<\/strong><\/p>\n\n\n\n<p>Octapharma AB<\/p>\n\n\n\n<p>112 75 Stockholm<\/p>\n\n\n\n<p><strong>Manufacturer:<\/strong><\/p>\n\n\n\n<p>Octapharma Pharmaceuticals<\/p>\n\n\n\n<p>Produktionsges.mbH<\/p>\n\n\n\n<p>Oberlaaerstr.&nbsp;235<\/p>\n\n\n\n<p>A-1100 Vienna<\/p>\n\n\n\n<p>Austria<\/p>\n\n\n\n<p><strong>Local representative:<\/strong><\/p>\n\n\n\n<p>Octapharma Nordic AB<\/p>\n\n\n\n<p>Lars Forssells gata 23<\/p>\n\n\n\n<p>112 75 Stockholm<\/p>\n\n\n\n<p>Phone 08-566 430 00<\/p>\n\n\n\n<p>Customer support: 020-311020<\/p>\n\n\n\n<p>e-mail: fraga@octapharma.se<\/p>\n\n\n\n<p>This medicine is approved in the European Economic Area under the names:<\/p>\n\n\n\n<p>Austria, Belgium, Bulgaria, Cyprus, Croatia, Czech Republic, Estonia, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovenia, Slovakia, Spain, Great Britain, Hungary:&nbsp;<strong>Wilate 500\/ Wilate 1000<\/strong><\/p>\n\n\n\n<p>Finland, Norway, Sweden:&nbsp;<strong>Wilate<\/strong><\/p>\n\n\n\n<p>Denmark:&nbsp;<strong>Wilnativ<\/strong><\/p>\n\n\n\n<p>France:&nbsp;<strong>Eqwilate 500\/ Eqwilate 1000<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wilate belongs to the pharmacotherapeutic group of drugs called coagulation factors and contains\u00a0human\u00a0von Willebrand factor (VWF) and\u00a0coagulation factor\u00a0VIII.\u00a0Both of these\u00a0proteins\u00a0are important for the blood&#8217;s ability to clot (\u00a0coagulation ability\u00a0).<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,22503],"tags":[13035,27714,13037,27939,13036,27938,27934,27936,27935,27937],"class_list":["post-31565","post","type-post","status-publish","format-standard","hentry","category-medicines","category-w","tag-coagulation-factor-viii","tag-human-von-willebrand-factor","tag-what-coagulation-factor-viii-is-used-for","tag-what-human-von-willebrand-factor-is-used-for","tag-what-is-coagulation-factor-viii","tag-what-is-human-von-willebrand-factor","tag-what-is-wilate","tag-what-wilate-is-used-for","tag-wilate","tag-wilate-side-effects"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/31565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=31565"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/31565\/revisions"}],"predecessor-version":[{"id":32088,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/31565\/revisions\/32088"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=31565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=31565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=31565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}